Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Some Anticancer Drugs Stop Working at a Hypoxia-Induced Phase Transition Point

By BiotechDaily International staff writers
Posted on 27 Jun 2013
By applying physical science analytical techniques and a basic understanding of the principles of thermodynamics to the problem of drug resistance in cancer cells with mTOR (mammalian target of rapamycin) mutations, cancer researchers identified a hypoxia-induced phase transition point at which mTOR suppressing drugs were no longer effective.

Hypoxia is a near-universal feature of solid tumors, promoting glycolysis, cellular proliferation, and angiogenesis. The molecular mechanisms of hypoxic signaling have been intensively studied, but the impact of changes in oxygen partial pressure (pO2) on the state of signaling networks is less clear. Similarly, it has been known that the behavior of mTOR signaling was influenced and altered by hypoxia, but the mechanism behind this was unknown.

Investigators at the Hebrew University of Jerusalem (Israel) and their colleagues at the California Institute of Technology (Pasadena, USA) and the University of California, Los Angeles (USA) worked with a glioblastoma multiforme (GBM) cancer cell model to examine the response of signaling networks to targeted pathway inhibition between 21% and 1% pO2 (oxygen partial pressure). For this study, they employed a microchip technology that facilitated quantification of a panel of functional proteins from statistical numbers of single cells. Results were interpreted using a set of theoretical tools derived from the physical sciences, which enabled the simplification of an otherwise complex biological system.

Results published in the April 9, 2013, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed that near 1.5% pO2, the mTOR signaling network - a critical component of hypoxic signaling and a compelling cancer drug target - was deregulated in a manner such that it became unresponsive to mTOR kinase inhibitors. While being unresponsive to mTOR kinase inhibitors near 1.5% pO2, cancer cells did respond at higher or lower pO2 values. These findings were validated through experiments on bulk GBM cell line cultures and on neurosphere cultures of a human-origin GBM xenograft tumor.

The investigators concluded that, "Our analysis—which may help explain the undistinguished performance of mTOR inhibitors in certain clinical trials—indicates that certain biologically complex cell behaviors may be understood using fundamental, thermodynamics-motivated principles."

Related Links:
Hebrew University of Jerusalem
California Institute of Technology
University of California, Los Angeles



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.